Qingsong Jiang

Prof. Qingsong Jiang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JZJie Zhang
Jie Zhang
HQHongmei Qiu
Hongmei Qiu
JHJiajun Huang
Jiajun Huang
SDShumei Ding
Shumei Ding
BHBo Huang
Bo Huang
QJQingsong Jiang
Qingsong Jiang
Cardiac hypertrophy is a key pathological process in the context of diabetic cardiomyopathy. Naringenin exhibits multiple pharmacological activities, but the effect of naringenin on cardiomyocyte hypertrophy under diabetic conditions is still far from clear. Cardiomyocyte hypertrophy was induced by high glucose (HG, glucose at 25.5 mmol/L) in H9c2 cells, which was determined by cell surface area, protein content and atrial natriuretic factor (ANF) mRNA expression. The effect of naringenin on cardiomyocyte hypertrophy was observed and its mechanisms were investigated by administration with various inhibitors on epoxyeicosatrienoic acids (EETs)/peroxisome proliferator-activated receptors (PPARs). The level of 14,15-EET was measured by ELISA. The mRNA and protein expressions were detected by qRT-PCR or Western blot, respectively. Naringenin (0.1, 1, 10 μmol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P < 0.05), up-regulated the expressions of PPARα, PPARβ, PPARγ and CYP2J3 (P < 0.05), and increased the level of 14,15-EET (P < 0.05). PPOH, a CYP2J3 inhibitor, blocked the naringenin-mediated improvement of myocardial hypertrophy (P < 0.01), and abolished the up-regulation of PPARs expressions (P < 0.01). Meanwhile, MK886, a PPARα antagonist, GSK0660, a PPARβ antagonist, and GW9662, a PPARγ antagonist, reversed the protection of naringenin on cardiomyocytes (P < 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P < 0.05). Activation of EETs and PPARs function together may be contributed to the anti-hypertrophic effect of naringenin in H9c2 cells under high glucose condition.

1 July 2019 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
SDShumei Ding
Shumei Ding
HQHongmei Qiu
Hongmei Qiu
JHJiajun Huang
Jiajun Huang
RCRongchun Chen
Rongchun Chen
JZJie Zhang
Jie Zhang
QJQingsong Jiang
Qingsong Jiang

7 December 2016 in Pharmaceutical Biology
Verified
Journal Article
Open access
HQHongmei Qiu
Hongmei Qiu
YWYang Wu
Yang Wu
QWQuanhua Wang
Quanhua Wang
CLChangqing Liu
Changqing Liu
LXLai Xue
Lai Xue
QJQingsong Jiang
Qingsong Jiang
Context: The available treatments for the abnormal proliferation of vascular smooth muscle cells (VSMCs) are still dismal. Berberine has been demonstrated to possess extensive medicine activity, yet relatively little is known about its effect on VSMCs proliferation. Many studies showed that PPARα and NO participated in the process of VSMCs proliferation. Objective: To evaluate the effect of berberine and its possible influence on PPARα-NO pathway in angiotensin IV-stimulated VSMCs. Materials and methods: The primary VSMCs were cultured with the tissue explants method, and the proliferation was characterized by MTT and protein content. Protein and mRNA expression were measured by Western blot and real-time RT-PCR, respectively. NO synthase (NOS) activity was measured using a spectrophotometric assay, and NO concentration was measured using the Griess assay. Results: Angiotensin IV (0.1 nmol/L)-induced VSMCs proliferation was evidenced by increasing the optical density at A490 and total protein content (p < 0.01), which was inhibited by berberine (10, 30 and 100 μmol/L) in a concentration-dependent manner (p < 0.05). Angiotensin IV decreased the expression of PPARα at mRNA and protein level (p < 0.05), which occurred in parallel with declining eNOS mRNA expression, NOS activity and NO concentration (p < 0.01). Berberine at 30 μmol/L reversed the effects of angiotensin IV in VSMCs (p < 0.05), which were abolished by MK 886 (0.3 μmol/L) (p < 0.05). Discussion and conclusion: The results support the therapeutic effects of berberine on angiotensin IV-induced proliferation in cultured VSMCs at least partially through targeting the PPARα-NO signalling pathway.

1 December 2018 in International Journal of Experimental Pathology
Verified
Journal Article
Closed access
PDF file
JZJie Zhang
Jie Zhang
HQHongmei Qiu
Hongmei Qiu
JHJiajun Huang
Jiajun Huang
SDShumei Ding
Shumei Ding
BHBo Huang
Bo Huang
QJQingsong Jiang
Qingsong Jiang

1 February 2020 in Neurochemistry International
Verified
Journal Article
Closed access
XHXiao Huan
Xiao Huan
COCheng Oumei
Cheng Oumei
QHQiu Hongmei
Qiu Hongmei
YJYang Junxia
Yang Junxia
MXMa Xiaojiao
Ma Xiaojiao
QJQingsong Jiang
Qingsong Jiang

15 January 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SLShujun Li
Shujun Li
BHBo Huang
Bo Huang
CZChangfei Zhou
Changfei Zhou
JSjingshan shi
jingshan shi
QWQin Wu
Qin Wu
QJQingsong Jiang
Qingsong Jiang
Cardiac hypertrophy is a major pathological process to result in heart failure and sudden death. Rutaecarpine, a pentacyclic indolopyridoquinazolinone alkaloid extracted from Evodia rutaecarpa with multiple pharmacological activities, yet the underlying protective effects and the mechanisms on cardiac hypertrophy remain unclear. This study aimed to evaluate the potential effects of rutaecarpine on pressure overload cardiac hypertrophy. Cardiac hypertrophy in rat was developed by abdominal aortic constriction (AAC) for 4 weeks, which was improved by rutaecarpine supplementation (20 or 40mg/kg/day, i.g.) for another 4 weeks. The level of angiotensin II was increased; the mRNA expression and the activity of calcineurin in the left ventricular tissue were augmented following cardiac hypertrophy. Rutaecarpine administration decreased angiotensin II content and reduced calcineurin expression and activity. Noteworthily, in angiotensin II-induced cardiomyocytes, rutaecarpine ameliorated the hypertrophic effects in a dose-dependent manner and downregulated the increased mRNA expression and activity of calcineurin. In conclusion, rutaecarpine can improve cardiac hypertrophy in pressure overload rats, which may be related to the inhibition of angiotensin II-calcineurin signal pathway.